在一名 HIV-1 感染者中发现两种不同克隆谱系的独特广泛中和抗体特异性：对疫苗设计的影响。
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
机构信息
Duke Human Vaccine Institute, Durham, North Carolina, USA.
出版信息
J Virol. 2012 Apr;86(8):4688-92. doi: 10.1128/JVI.07163-11. Epub 2012 Feb 1.
Abstract
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.
摘要
从一小部分慢性感染 HIV-1 的个体的血浆中可以观察到显著的中和活性幅度和广度。从其中一个个体（CH0219）中，我们从具有不同特异性的记忆 B 细胞的两个克隆谱系中分离出两种广泛中和抗体（bnAbs），CH01 和 VRC-CH31，分别具有可变环 1 和 2（V1V2）构象特异性和 CD4 结合位点特异性，分别 recapitulate 95%的 CH0219 血清中和广度。这些数据为旨在引发多种特异性 bnAbs 的 HIV-1 疫苗提供了概念验证。
相似文献
1
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
J Virol. 2012 Apr;86(8):4688-92. doi: 10.1128/JVI.07163-11. Epub 2012 Feb 1.
2
Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
J Virol. 2016 Nov 14;90(23):10574-10586. doi: 10.1128/JVI.01012-16. Print 2016 Dec 1.
3
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
J Virol. 2018 Feb 12;92(5). doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.
4
Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
J Virol. 2016 Oct 28;90(22):10220-10235. doi: 10.1128/JVI.01357-16. Print 2016 Nov 15.
5
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.
6
Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
mBio. 2021 Aug 31;12(4):e0127421. doi: 10.1128/mBio.01274-21. Epub 2021 Jul 20.
7
Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Antiviral Res. 2016 Aug;132:252-61. doi: 10.1016/j.antiviral.2016.06.013. Epub 2016 Jul 5.
8
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
Nature. 2013 Apr 25;496(7446):469-76. doi: 10.1038/nature12053. Epub 2013 Apr 3.
9
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.
J Virol. 2012 Jul;86(14):7496-507. doi: 10.1128/JVI.00426-12. Epub 2012 May 2.
10
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.
J Virol. 2015 Oct 14;90(1):76-91. doi: 10.1128/JVI.01791-15. Print 2016 Jan 1.
引用本文的文献
1
Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope.
NPJ Vaccines. 2025 Aug 5;10(1):185. doi: 10.1038/s41541-025-01235-5.
2
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV.
Structure. 2025 Jul 3;33(7):1150-1164.e8. doi: 10.1016/j.str.2025.04.016. Epub 2025 May 14.
3
Dynamics and activation of membrane-bound B cell receptor assembly.
Commun Biol. 2025 Feb 13;8(1):226. doi: 10.1038/s42003-025-07478-1.
4
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIV infection.
Nat Commun. 2024 Aug 29;15(1):7461. doi: 10.1038/s41467-024-51848-y.
5
The CH1 domain influences the expression and antigen sensing of the HIV-specific CH31 IgM-BCR and IgG-BCR.
Proc Natl Acad Sci U S A. 2024 Jul 30;121(31):e2404728121. doi: 10.1073/pnas.2404728121. Epub 2024 Jul 23.
6
Dynamics and Activation of Membrane-Bound B Cell Receptor Assembly.
bioRxiv. 2024 Dec 4:2024.07.10.602784. doi: 10.1101/2024.07.10.602784.
7
: a tool for high throughput binding kinetics data analysis for multiple label-free platforms.
Gates Open Res. 2024 Jun 28;7:107. doi: 10.12688/gatesopenres.14743.1. eCollection 2023.
8
Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1.
Front Immunol. 2023 Oct 3;14:1271686. doi: 10.3389/fimmu.2023.1271686. eCollection 2023.
9
Parameter estimation and identifiability analysis for a bivalent analyte model of monoclonal antibody-antigen binding.
Anal Biochem. 2023 Oct 15;679:115263. doi: 10.1016/j.ab.2023.115263. Epub 2023 Aug 6.
10
Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning.
Cell Host Microbe. 2023 Jul 12;31(7):1200-1215.e9. doi: 10.1016/j.chom.2023.05.025. Epub 2023 Jun 15.
本文引用的文献
1
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.
J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.
2
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532. Epub 2011 Aug 11.
3
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.
J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27.
4
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.
5
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.
6
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9.
7
Induction of immunity to human immunodeficiency virus type-1 by vaccination.
Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011.
8
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.
Nature. 2010 Sep 30;467(7315):591-5. doi: 10.1038/nature09385.
9
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.
10
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.
Zotero 插件